Product Name	:	Dacomitinib
Synonyms	:	PF-00299804;PF-299804;PF 299804;PF 00299804
Cat No.	:	M10413
CAS Number	:	1110813-31-4
Molecular Formula	:	C24H25ClFN5O2
Formula Weight	:	469.90
Chemical Name	:	2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-
Description	:	Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively; irreversibly inhibits erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members inhibits erbB1 autophosphorylation in the A431 human squamous cell carcinoma line with IC50 of 15.1 nM; causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in EGFR associated with resistance to gefitinib and erlotinib.Lung Cancer Phase 3 Clinical
Pathway	:	Angiogenesis
Target	:	EGFR
Receptor	:	EGFR;HER2/ErbB2
Solubility	:	DMSO: ≥ 50 mg/mL (Need ultrasonic)
SMILES	:	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
Storage	:	(-20℃)
Stability	:	≥ 2 years
Reference	:	



1. Engelman JA, et al. Cancer Res. 2007 Dec 15;67(24):11924-32.| 2. Gonzales AJ, et al. Mol Cancer Ther. 2008 Jul;7(7):1880-9.| 3. Nguyen KS, et al. Clin Lung Cancer. 2009 Jul;10(4):281-9.| 4. Kalous O, et al. Mol Cancer Ther. 2012 Sep;11(9):1978-87.